A locally developed COVID-19 vaccine prospect in Nigeria, listed by the World Health Organisation (WHO) among 183 others in preclinical trials globally, might cost more to manufacture than the relatively pricey Pfizer-BioNTech and even the considerably cheap AstraZeneca vaccines.
Adopted from Business Day